Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

1. Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection.Immunology · 2026
   Article
2. Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026
   Review
3. Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026
   Review
4. CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.iScience · 2026
   Article
5. CD57-Expressing Lymphocytes: From Chronic Viral Response to Age-Related Inflammation.Cells · 2026
   Review
6. The Human Respiratory Virome in Health and Disease: Interactions, Dysbiosis, and Methodological Challenges.Advanced genetics (Hoboken, N.J.) · 2025
   Review
7. Global research trends of immunosenescence and immunotherapy: A bibliometric study.Human vaccines & immunotherapeutics · 2025
   Review
8. Prognostic value of CD28⁻CD57⁺CD8⁺ T cells for early immunotherapy response in hepatocellular carcinoma: a prospective observational study.Scientific reports · 2025
   Observational
9. The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
   Review
10. Mapping CMV-related immune signatures in blood, aorta and perivascular mediastinal adipose tissue.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
11. Evaluating the Safety and Efficacy of PD-1 Inhibitors in HIV Patients Diagnosed with Lung Cancer: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
12. A Human Immuno-Lung Organoid Model to Study Macrophage-Mediated Lung Cell Senescence Upon SARS-CoV-2 Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
13. Safety and Efficacy of Immune Checkpoint Inhibitors in Human Immunodeficiency Virus-Associated Cancer: A Systematic Scoping Review.Diseases (Basel, Switzerland) · 2025
    Review
14. Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines.Clinical and experimental immunology · 2025
    Article
15. Application of targeted next-generation sequencing for pathogens diagnosis and drug resistance prediction in bronchoalveolar lavage fluid of pulmonary infections.Frontiers in cellular and infection microbiology · 2025
    Article
16. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.Journal for immunotherapy of cancer · 2024
    Observational
17. Clinical application of targeted next-generation sequencing in severe pneumonia: a retrospective review.Critical care (London, England) · 2024
    Article
18. Antibody signatures against viruses and microbiome reflect past and chronic exposures and associate with aging and inflammation.iScience · 2024
    Article
19. Divergent local and systemic antitumor response in primary uveal melanomas.The Journal of experimental medicine · 2024
    Article
20. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment.npj aging · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

22 authors at 5 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as